Ipsen’s Cabometyx approved for renal cell carcinoma by NICE

Ipsen's cancer drug Cabometyx has been approved for the treatment of advanced renal cell carcinoma by the UK's National Institute for Health and Care Excellence (NICE).

The approval means that renal cell carcinoma patients in England and Wales will be able to receive Cabometyx through the NHS following prior vascular endothelial growth factor-targeted therapy.

NICE determined that the drug has the potential to offer additional benefits to some patients due to its multi-targeting mechanism of action, with the decision based on positive data from phase III clinical trials.

Cabometyx has been shown to elicit a response rate in five times as many patients as an established alternative, while also extending median overall and progression-free survival rates.

Up until this point, Ipsen has been running a managed access programme across the UK that provides this drug free of charge to patients for the duration of their treatment, but this will no longer be necessary.

Ewan McDowall, vice-president of commercial operations for Ipsen in the UK and Ireland,  said: "To date, nearly 300 patients in the UK have benefited from cabozantinib through this Ipsen initiative, whilst the NICE process took place. We are delighted that now any eligible patients in the UK can benefit from cabozantinib."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.